These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [The pro-arrhythmic effects of anti-arrhythmia agents]. Haverkamp W; Wichter T; Chen X; Hördt M; Willems S; Rotman B; Hindricks G; Kottkamp H; Borggrefe M; Breithardt G Z Kardiol; 1994; 83 Suppl 5():75-85. PubMed ID: 7846949 [TBL] [Abstract][Full Text] [Related]
3. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management. Hohnloser SH Am J Cardiol; 1997 Oct; 80(8A):82G-89G. PubMed ID: 9354415 [TBL] [Abstract][Full Text] [Related]
4. Mechanisms and risk factors for proarrhythmia with type Ia compared with Ic antiarrhythmic drug therapy. Levine JH; Morganroth J; Kadish AH Circulation; 1989 Oct; 80(4):1063-9. PubMed ID: 2676234 [TBL] [Abstract][Full Text] [Related]
5. Proarrhythmia during drug treatment of supraventricular tachycardia: paradoxical risk of sinus rhythm for sudden death. Prystowsky EN Am J Cardiol; 1996 Oct; 78(8A):35-41. PubMed ID: 8903274 [TBL] [Abstract][Full Text] [Related]
6. Proarrhythmia. Friedman PL; Stevenson WG Am J Cardiol; 1998 Oct; 82(8A):50N-58N. PubMed ID: 9809901 [TBL] [Abstract][Full Text] [Related]
7. Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. Hohnloser SH; Singh BN J Cardiovasc Electrophysiol; 1995 Oct; 6(10 Pt 2):920-36. PubMed ID: 8548113 [TBL] [Abstract][Full Text] [Related]
8. Proarrhythmia. Naccarelli GV; Wolbrette DL; Luck JC Med Clin North Am; 2001 Mar; 85(2):503-26, xii. PubMed ID: 11233957 [TBL] [Abstract][Full Text] [Related]
9. Clinical types of proarrhythmic response to antiarrhythmic drugs. Bigger JT; Sahar DI Am J Cardiol; 1987 Apr; 59(11):2E-9E. PubMed ID: 3554950 [TBL] [Abstract][Full Text] [Related]
10. [Torsades de pointes ventricular tachycardia induced by intravenous amiodarone]. Makai A; Rudas L; Liszkai G; Fazekas T Orv Hetil; 2003 Feb; 144(5):241-7. PubMed ID: 12647553 [TBL] [Abstract][Full Text] [Related]
11. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Hondeghem LM; Carlsson L; Duker G Circulation; 2001 Apr; 103(15):2004-13. PubMed ID: 11306531 [TBL] [Abstract][Full Text] [Related]
12. [The pro-arrhythmia effects of anti-arrhythmia agents--theoretical and clinical aspects]. Steinbeck G Z Kardiol; 1992; 81 Suppl 4():139-43. PubMed ID: 1290290 [TBL] [Abstract][Full Text] [Related]
13. What have clinical trials taught us about proarrhythmia? Skanes AC; Green MS Can J Cardiol; 1996 Apr; 12 Suppl B():20B-26B. PubMed ID: 8616725 [TBL] [Abstract][Full Text] [Related]
14. Mechanisms and management of proarrhythmia. Roden DM Am J Cardiol; 1998 Aug; 82(4A):49I-57I. PubMed ID: 9737654 [TBL] [Abstract][Full Text] [Related]
15. From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials. Lazzara R Am J Cardiol; 1996 Aug; 78(4A):28-33. PubMed ID: 8780326 [TBL] [Abstract][Full Text] [Related]
16. Proarrhythmia. Roden DM; Anderson ME Handb Exp Pharmacol; 2006; (171):73-97. PubMed ID: 16610341 [TBL] [Abstract][Full Text] [Related]
17. [Antiarrhythmic therapy in patients with heart failure]. Faber TS; Zehender M Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993 [TBL] [Abstract][Full Text] [Related]
18. Amiodarone and torsades de pointes in patients with advanced heart failure. Middlekauff HR; Stevenson WG; Saxon LA; Stevenson LW Am J Cardiol; 1995 Sep; 76(7):499-502. PubMed ID: 7653452 [TBL] [Abstract][Full Text] [Related]
19. Drug-induced torsade de pointes. Incidence, management and prevention. Faber TS; Zehender M; Just H Drug Saf; 1994 Dec; 11(6):463-76. PubMed ID: 7727055 [TBL] [Abstract][Full Text] [Related]